Tag: halved-the-risk
-
‘New day’ in lung cancer as Merck drug shines, works with chemo
By Ben Hirschler COPENHAGEN (Reuters) – Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths…
-
‘New day’ in lung cancer as Merck drug shines, works with chemo
By Ben Hirschler COPENHAGEN (Reuters) – Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemotherapy. As a monotherapy, Keytruda halved the risk of disease progression and cut overall deaths…
-
Roche lung cancer drug success adds to pressure on Bristol
By Ben Hirschler COPENHAGEN (Reuters) – Lung cancer patients on Roche’s immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study, pressuring Bristol-Myers Squibb’s dominant position in the field. The trial involved second-line patients, who have already used chemotherapy, and it found the Roche drug worked even…